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ABSTRACT
Background: This study presents a framework for determining the allocation and 
distribution of the limited amount of vaccines against severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2).
Methods: After analyzing the pandemic strategies of the major organizations and countries 
and with a literature review conducted by a core panel, a modified Delphi survey was 
administered to 13 experts in the fields of vaccination, infectious disease, and public health 
in the Republic of Korea. The following topics were discussed: 1) identifying the objectives 
of the vaccination strategy, 2) identifying allocation criteria, and 3) establishing a step-by-
step vaccination framework and prioritization strategy based on the allocation criteria. Two 
rounds of surveys were conducted for each topic, with a structured questionnaire provided via 
e-mail in the first round. After analyzing the responses, a meeting with the experts was held 
to obtain consensus on how to prioritize the population groups.
Results: The first objective of the vaccination strategy was maintenance of the integrity 
of the healthcare system and critical infrastructure, followed by reduction of morbidity 
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and mortality and reduction of community transmission. In the initial phase, older adult 
residents in care homes, high-risk health and social care workers, and personal support 
workers who work in direct contact with coronavirus disease 2019 (COVID-19) patients would 
be prioritized. Expansion of vaccine supply would allow immunization of older adults not 
included in phase 1, followed by healthcare workers not previously included and individuals 
with comorbidities. Further widespread vaccine supply would ensure availability to the 
extended adult age groups (50–64 years old), critical workers outside the health sector, 
residents who cannot socially distance, and, eventually, the remaining populations.
Conclusion: This survey provides the much needed insight into the decision-making process 
for vaccine allocation at the national level. However, flexibility in adapting to strategies will 
be essential, as new information is constantly emerging.
Keywords: COVID-19; Vaccines; Policy; Distribution; Survey; Korea
INTRODUCTION
The ongoing coronavirus disease 2019 (COVID-19) pandemic has infected over 130 million 
people globally, resulting in 2,842,325 deaths as of April 4, 2021.1 To achieve a protection 
threshold in the population, 67% of people would have to develop natural immunity.2 Despite 
the increased number of infections, this seems difficult to attain, as studies in the United 
States (US) reported low rates of patients with antibodies to the severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) (< 24%), even after the large wave in the winter.3 
Similarly, poor results were reported in the European Union/European Economic Area (EU/
EEA) (1.0–8.5%)4,5 and the Republic of Korea (< 1.0%).6,7 Thus, it seems that vaccination is 
necessary to reach the protective threshold.
As of April 2, 2021, 28 vaccine candidates entered phase 3 of clinical trials.8 It is expected that 
74% of phase 3 vaccines will be approved.9 Nevertheless, an initial limitation in the supply 
is expected because of manufacturing issues. The crucial question arising is who gets first 
access to vaccines when they become available.
During the previous H1N1 influenza pandemic in 2009, many countries (including Republic of 
Korea) applied step-by-step strategies according to vaccine supply. The Advisory Committee 
on Immunization Practices (ACIP) in the US has steadily updated guidelines on allocating and 
targeting vaccines during influenza pandemics.10,11 Currently, these principles have informed 
the ACIP's strategy concerning the COVID-19 vaccination. However, the SARS-CoV-2 is 
remarkably different from influenza, and new vaccine allocation protocols are necessary.
Unlike the 2009 pandemic, the incidence or severity of COVID-19 infection is relatively 
low in children and adolescents, and severe morbidity and mortality are prevalent in the 
older population. Transmission-related risk groups are also difficult to clearly define.12,13 
Thus, considering the characteristics of COVID-19 known to date, the major organizations 
and countries, such as the World Health Organization (WHO), US, and United Kingdom 
(UK), suggest allocating the first batch of COVID-19 vaccines to healthcare personnel 
and populations at high risk of severe morbidity and mortality, such as older persons and 
persons with comorbidities.14-16 However, the range or ranking of each target population has 
not yet been specified in most countries, and the inclusion of high-exposure occupations 
varies between countries. The detailed strategy of each country should be based on its own 
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situations, such as epidemiology, financial status, public acceptance, and availability of 
vaccine doses.
During the study period, it was not known which vaccines would be approved, although the 
minimum criteria for approval recommended by the WHO were presented,17 and the priority 
would vary depending on the characteristics of vaccines to be developed. Nevertheless, at 
this point, a draft of the preliminary strategy for allocation of the COVID-19 vaccine reflecting 
the domestic situation was necessary for vaccine introduction. The present study discusses 
and proposes foundational objects and outlines a framework for the allocation of COVID-19 
vaccines in the Republic of Korea.
METHODS
In the present study, three topics were discussed to create a framework for the allocation 
and prioritization of COVID-19 vaccination: 1) identifying the objectives of the vaccination 
strategy, 2) identifying the allocation criteria, and 3) establishing a step-by-step vaccination 
framework and prioritization strategy based on allocation criteria (Fig. 1). To manage the 
task, two panels were convened: a core panel and an expert panel. The core panel, consisting 
of 6 researchers, was the strategic steering group that oversaw the task. The modified 
Delphi technique was used, where the core panel collected updated data and background 
evidence, provided a structured questionnaire, hosted online meetings, and gathered expert 
opinions. The expert panel consisted of 13 relevant experts. This study was conducted from 
July 23, 2020, to October 31, 2020. Specifically, the survey on the first topic was carried out 
from August 11, 2020, to August 21, 2020; on the second topic, from August 21, 2020, to 
September 21, 2020; and, on the last topic, from September 21, 2020 to October 31, 2020 
based on the previous surveys. During this period, the vaccination strategies of several 
organizations and countries were being updated.18-23 By referencing these standards and with 
an additional systematic review,15,24,25 the panels devised a strategy suitable for the domestic 
situation. The process was as follows:
First, the core panels reviewed previous pandemic and vaccine strategies of major 
organizations and countries, assessed the progress of vaccine development, and prepared 
background evidence reports for each topic. Second, the standards were selected from 
representative frameworks and modified for the Korean situation. The core panel created 
and provided a structured questionnaire using the modified evidence. Third, expert opinions 
were gathered through several rounds of the modified Delphi technique. Fourth, the 
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Fig. 1. Process of creating a framework for allocation and prioritization of coronavirus disease 2019 vaccination.
framework was completed through expert consensus and revision by the core panel. As the 
time period required to obtain enough vaccines was not known, the researchers considered 
the initial supply of vaccine to be tightly constrained, enough for only approximately 3–5% 
of the Korean population.18,26 Since vaccine supply would be phased incrementally with 
increasing supply, the researchers planned to list target groups according to how the vaccine 
would be secured in approximately 5 phases.
Research design
Two rounds of surveys were conducted for each topic, and a structured questionnaire was 
provided via e-mail in the first round. The questionnaire comprised close-ended questions 
(e.g., scoring level of consent, risk assessment) and open-ended questions. After the first 
round, the core panel calculated the aggregate ratings and summarized the comments. 
The responses to the open-ended questions in the first round were reflected in the second 
questionnaire after a discussion within the core panel. The second round of surveying was 
conducted through online meetings, where the results of the first round of the survey were 
shared and expert consensus was reached through discussion and voting (Fig. 2).
Data analysis
Expert opinions on the objectives, allocation criteria, and classification of the population 
group were mainly collected in the form of consensus. The experts answered the items in 
the structured questionnaire using a 9-point Likert scale, and the results were summed. If 
≥ 30% of the experts rated an item in the lower third (ratings 1–3) and ≥ 30% rated it in the 
upper third (ratings 7–9), it was considered a “disagreement.” We regarded quality criteria 
with an overall median rating of 7 to 9, without disagreement, as “appropriate” or “building 
consensus.” We considered criteria with a median rating of 1 to 6 as “inappropriate” 
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Fig. 2. Process of building consensus (the modified Delphi consensus process).
or “failed to reach consensus.” The criteria that elicited disagreement were considered 
“inappropriate.”27 During the second round of the survey, the results of the first survey were 
discussed and re-voted on. If the result of a certain question was still “inappropriate” in the 
second round, the question was eliminated or re-voting was held through discussion.
Prioritization was identified using a slightly different method. In the first round, each target 
population group was rated on a 5-point scale based on the allocation criteria. The mean and 
standard deviation of the ratings for each population group were calculated separately for 
each criterion. Using this result as a reference, the ranking of each group was determined 
in the second round of the survey. The ranking was carried out to determine the group that 
ranked first among the remaining population groups (Fig. 2). When two-thirds of the experts 
selected a certain group, it was considered as “building consensus.” If less than two-thirds 
agreed, re-voting was conducted after sufficient discussion. If consensus was still not reached 
after the second vote, the decision was withheld and discussed again after all rankings were 
made to determine their ranking or to classify them in the same tier. Since it was important to 
determine the ranking in the context of limited vaccine supply, only the rankings corresponding 
to 50–60% of the total population were discussed. After listing them from first to last, the 
target groups to be vaccinated in 5 phases were listed in a step-by-step manner.
RESULTS
Participants
The expert panel consisted of 13 experts representing the relevant associations/societies: 3 
experts each from the Korean Society of Infectious Diseases, Korean Vaccine Society, Korean 
Society of Pediatric Infectious Diseases, and Korean Society of Epidemiology and 1 expert 
from the National Central Clinical Committee.
Step 1: Identifying the objectives of the vaccination strategy
All members of the expert panel responded to the first and second rounds of the survey 
to set the objectives of vaccination. All experts showed a high level of agreement with the 
inclusion of all the items in the questionnaire (Table 1). After a discussion in the second 
round, the inclusion objectives were ranked according to their level of agreement (mean score 
on the 9-point Likert scale). The most prioritized objective was to “protect the integrity of 
the healthcare system and critical infrastructure,” followed by “reduction in morbidity and 
mortality” and “prevention of transmission within community.”
Step 2: Identifying allocation criteria
All members of the expert panel responded to the first and second rounds of the survey. In 
the first round, all items in the questionnaire were considered appropriate for inclusion in 
the allocation criteria (Table 2). Based on the items selected in the first round, the experts 
were asked to rate the relative importance of each item on a scale of 1 (least importance) to 
5 (absolutely necessary) in the second round to rank the items. The rankings are presented 
in Table 2. The risks of severe morbidity and mortality were the highest priority, followed 
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Table 1. Identifying objectives of vaccination
Item Agreement among 13 experts (mean scores on 9-point Likert scale) Ranking
Protect the integrity of the healthcare system and the critical infrastructure High level of agreement and appropriateness (8.6) 1
Reduce morbidity and mortality High level of agreement and appropriateness (8) 2
Reduce transmission within community High level of agreement and appropriateness (7.5) 3
by protection of healthcare infrastructure and other societal functions, risk of transmission 
to vulnerable populations, and risk of acquiring infection. Implementation was ranked the 
lowest, and equity considerations were excluded from the criteria.
Step 3: Establishing a step-by-step vaccination framework and prioritization 
strategy based on the allocation criteria
Category of and estimated number in the population group
The framework for allocating and targeting the initial vaccination of certain groups included 
a structure that classified the population into 4 broad categories corresponding to the 
objectives of the vaccination program: 1) providing healthcare and community support, 2) 
providing COVID-19-related support, 3) maintaining critical infrastructure, and 4) the general 
population. These 4 categories covered the entire population. Each of these categories 
further included specific subpopulations defined by occupation, age, health status, or place 
of residence. The categories, population groups, and estimated numbers for each group are 
presented in Table 3.
Round 1: Scores for each group based on allocation criteria
All members of the expert panel responded to the first round of the survey and rated each 
population group on a 5-point scale based on the allocation criteria. Table 4 outlines the means 
and standard deviations of the scores given by the 13 experts for each population group.
Based on the average score, the 5-point scale was divided into 3 sections, marked in different 
colors, referred to as low, medium, and high scores. Healthcare workers, individuals 
working in COVID-19 support services, and older adults in congregated or overcrowded 
settings received high scores on ≥ 3 criteria. The remaining older adults, individuals with 
comorbid conditions, and the group comprising police officers, firefighters, and soldiers 
received medium-to-high scores on more than half of the criteria. Household contacts 
with older adults or people with comorbidities and other critical workers had high scores 
in one criterion (the risk of transmission to vulnerable populations and protection of social 
function, respectively), but overall low scores in other criteria.
Round 2: Prioritization and establishment of a vaccination framework
Using the results of Round 1 as a reference, each group was ranked by voting in the second 
round of the survey (Fig. 2, Supplementary Table 1). Ten to eleven experts (77–85%) 
participated in the second round. Six votes were used to rank the population groups. Since an 
increase in vaccine production over time was expected, the remaining half of the population 
that was not ranked by voting was largely divided into 2 groups (Supplementary Tables 1 and 
2). Considering the voting results and rankings, estimated population numbers, and vaccine 
amount-securing scenarios, Table 5 and Supplementary Fig. 1 show the framework of the 
vaccine allocation strategy in 5 phases.
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Table 2. Allocation criteria
Criteria candidate Round 1: Rating Round 2: Ranking
Risk of severe morbidity and mortality 8.8 ± 0.4 1
Protection of healthcare infrastructure and other societal functions 8.4 ± 0.8 2
Risk of transmission to vulnerable populations 8.2 ± 0.7 3
Implementation 7.7 ± 1.0 5
Risk of acquiring infection 7.5 ± 2.2 4
Equity considerations 6.0 ± 2.8 Exclude
Values are presented as mean ± standard deviation not otherwise specified.
Older adult residents in care homes and high-risk health and social care workers (in terms 
of risk of transmission to vulnerable persons and acquiring infection) would be given the 
top priority. It was difficult to determine how to prioritize the 2 groups even after several 
discussions. As they comprise only less than 5% of the total population, the 2 groups were 
jointly ranked first. Another group included in the first phase was COVID-19 support workers 
(first responders, emergency medical technicians), as they had a similar level of risk as the 
high-risk health and social care workers in the first-round survey.
In phase 2, all older adults not included in phase 1 were included. Considering the incidence 
of COVID-19 infection across different ages in the Republic of Korea,13 older adults were 
defined as those aged ≥ 65 years. However, if the amount of vaccine doses was insufficient, 
this group could be further subdivided into 5-year intervals and considered for vaccination, 
starting from the older age group.
In phase 3, expansion of vaccine supply would allow for the immunization of another cohort 
of individuals with comorbid conditions and healthcare workers not included in phase 1. 
Adults aged 50–64 years might be considered as an alternative to those with comorbidity 
due to the high proportion of comorbid conditions among them28 and for improved 
implementation. Nevertheless, individuals with comorbid conditions had clear benefits of 
vaccination in terms of the risk of severe morbidity and mortality29; therefore, it was decided 
that they had to be given high priority.
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Table 3. Category, population group, and estimated number of each population group
Category Population group Estimated number 
(% of total 
populationa)
Reference or relevant 
instituteb
Health care and community 
support services
High risk workers in healthcare facilities, workers in long-term care facilities/home 
welfare facilities
1,395,000 (2.7) MOHW, data obtained 
from HIRA
Other healthcare workers
COVID-19 support services First responders (patient management, isolation, epidemiological investigation, 
quarantine), emergency medical technicians
92,000 (0.2) Local municipalities, 
KNFA
Other critical infrastructure Police, firefighters, soldiers 745,000 (1.4) KNPA, KNFA, MND
Critical infrastructure workers who are indispensable for the public to maintain daily 
life (e.g., energy and water supply, transportation system)
159,900 (0.3) K-water, MOTIE, MOLIT
General population Infants & children (0–6 years) 2,614,420 (5.0) Statistics Korea 43
Elementary school aged children (7–12 year) 2,827,468 (5.5)
Middle and high school aged children (13–18 year) 2,849,595 (5.5)
Adults 19–49 years old 22,663,859 (43.7)
Adults 50–64 years old 12,525,494 (24.2)
Older adults (≥65 years old) 8,359,117 (16.1)
Adults aged 19–64 years old with significant comorbid conditions 6,026,894 (12.1) Data obtained from 
HIRAcAdults aged 19–64 years old with moderate comorbid conditions 5,647,911 (11.4)
Older adults in congregated or overcrowded settingsd 566,400 (1.1) Data obtained from HIRA
Persons in congregated or overcrowded setting (except older adults)e 63,927 (0.1) Statistics of MOHW44
Child/adolescent education facility workers and staff 675,000 (1.3) Statistics of MOE45
Incarcerated/detained people and staff 19,570 (0.04) MOJ
Pregnant women 295,000 (0.6) Data obtained from HIRA
Household contacts of older adults or people with comorbid conditions Not available
MOHW = Ministry of Health and Welfare, KNFA = Korean National Fire Agency, KNPA = Korean National Police Agency, MND = Ministry of National Defense, 
K-water = Korea Water Resource Corporation, MOTIE = Ministry of Trade, Industry and Energy, MOLIT = Ministry of Land, Transport and Maritime Affairs, MOE = 
Ministry of Education, HIRA = Health Insurance Review and Assessment Service, MOJ = Ministry of Justice.
aCalculation based on the total population reported to Statistics Korea as of August 2020. The results extracted from the health insurance claims data were based on 
the total population of the data source. Owing to overlapping cases, the total proportion exceeded 100%; bThe number of population groups was estimated through 
relevant reference or by direct request to a relevant institute (unpublished data); cSince the amount of vaccines would be limited, the number of individuals with 
comorbidities that put them at higher risk was estimated by dividing them into significant and moderate groups, according to the Centers for Disease Control and 
Prevention classification as of September 2020.34 The number of individuals with significant or moderate comorbidity was estimated using Korean claims data (from 
April 2019 to May 2020); dThis includes residents of healthcare and non-healthcare congregate settings (e.g., group homes, long-term care facilities); eCenters for 
children; single parents; disabled people; mental health patients; people with unstable housing, tuberculosis, and Hansen's disease; and women's shelters.
In phase 4, the vaccine supply would become widely available and allow broader 
immunization. Since the severity of COVID-19 is found to increase in patients aged 50 years 
and over in the Republic of Korea, adults aged 50–64 years were placed under this phase. 
Individuals at high risk of exposure due to occupation or place of residence and critical 
infrastructure workers outside the healthcare sector were included in this phase. In addition, 
despite the possible difficulties in implementation, people living with older adults or those 
with comorbidities were recommended to get vaccinated in this phase.
Finally, once vaccine supply becomes widely available (phase 5), vaccines would be made 
available to children and healthy young adults. An important issue here is that broad 
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Table 4. Score of each target population based on allocation criteria (results based on opinions of 13 experts)









Risk of acquiring 
infection
Implementation
High-risk healthcare workers 2.6 ± 1.0 4.8 ± 0.4 4.8 ± 0.4 4.7 ± 0.5 4.8 ± 0.4
Other healthcare workers 2.4 ± 0.9 3.7 ± 0.8 3.8 ± 1.1 3.5 ± 0.8 3.8 ± 0.9
COVID-19 support services 2.5 ± 1.1 4.8 ± 0.4 3.8 ± 0.8 4.8 ± 0.4 4.5 ± 0.7
Police, firefighters, soldiers 1.7 ± 0.6 4.4 ± 1.0 2.1 ± 0.8 2.6 ± 0.8 3.7 ± 1.2
Other critical workersa 1.7 ± 0.6 3.8 ± 0.9 1.9 ± 0.8 2.1 ± 0.8 2.7 ± 0.8
Preschool children (0–6 years) 1.3 ± 0.5 1.1 ± 0.3 2.4 ± 1.0 1.6 ± 0.5 1.8 ± 0.8
Elementary school age (7–12 years) 1.2 ± 0.4 1.1 ± 0.3 2.0 ± 0.7 2.0 ± 0.6 2.1 ± 1.0
Middle/high school age (13–18 years) 1.2 ± 0.4 1.2 ± 0.4 1.6 ± 0.8 2.4 ± 0.5 2.3 ± 0.9
Adults (19–49 years) 1.5 ± 0.5 1.9 ± 1.0 2.0 ± 0.9 2.8 ± 0.7 1.9 ± 0.8
Adults (50–64 years) 2.7 ± 0.9 2.0 ± 1.0 2.2 ± 1.2 2.8 ± 0.7 2.6 ± 0.9
Older adults (≥ 65 years) 4.3 ± 0.6 1.4 ± 0.8 3.5 ± 0.8 2.9 ± 1.0 3.6 ± 0.8
Older adults residing in care homes 5.0 ± 0.0 1.2 ± 0.6 4.8 ± 0.4 3.8 ± 1.1 4.6 ± 0.5
Adults with significant comorbidity 4.5 ± 0.5 1.7 ± 0.9 2.5 ± 1.1 2.7 ± 0.9 3.5 ± 1.0
Adults with moderate comorbidity 3.9 ± 0.6 1.8 ± 0.8 2.3 ± 0.8 2.5 ± 0.8 2.9 ± 0.9
People in group homes (except older adults) 2.5 ± 1.1 1.4 ± 0.7 2.7 ± 1.1 3.1 ± 0.9 3.3 ± 0.9
Teachers and relevant staff 1.5 ± 0.5 2.8 ± 0.8 2.0 ± 1.1 2.3 ± 0.6 2.6 ± 0.8
Incarcerated/detained people and staff 2.1 ± 0.8 2.4 ± 1.4 2.2 ± 1.0 2.6 ± 1.1 3.0 ± 1.0
Pregnancy 2.5 ± 1.1 1.5 ± 0.8 1.8 ± 0.9 1.8 ± 0.6 2.0 ± 1.2
Close contacts of older adults or people with comorbid conditions 1.8 ± 0.7 1.7 ± 0.9 4.0 ± 1.1 2.5 ± 0.8 2.4 ± 1.0
Each population group was rated on a 5-point scale based on the allocation criteria: 1 (least importance) to 5 (absolute importance). The mean values of the 
13 experts' opinions are indicated. Based on the mean value, the 5-point scale was divided into 3 equal parts and marked in different colors: 1 to 2.3 points, 
white (low score); above 2.3 and less than 3.6, light orange (medium score); and above 3.6, dark orange (high score). Values are presented as mean ± standard 
deviation of 5-point scale.
aCritical infrastructure workers who are indispensable for the public to maintain daily life (e.g., energy and water supply, transportation system).
Table 5. Framework of the allocation and prioritization of COVID-19 vaccination according to expected vaccine availability
Phase Priority population
Phase 1 (~5%) - Older adults in congregated or overcrowded settings
- High-risk workers in healthcare facilities, workers of long-term care facilities/home welfare facilities
- First responders, emergency medical technicians
Phase 2 (~10–20%) - Older adults (≥ 65 years old): If the quantity is insufficient, consider subdividing into 5-year-units
Phase 3 (~40–45%) - Other healthcare workers
- Adults aged 19–64 years with comorbid conditions (significant/moderate)
Phase 4 (~50–60%) - Adults aged 50–64 years
- Police, firefighters, soldiers
- Other critical infrastructure workers who are indispensable for the public to maintain daily living life
- Children/adolescent education facility workers and staff
- Persons in congregate or overcrowded setting (excluding older adults)
- Incarcerated/detained people and staff
- Household contacts of older adults or people with comorbid condition
Phase 5 (~100%) - Remaining adults aged 19–49 years
- Infants/children (0–18 years)
COVID-19 = coronavirus disease 2019.
immunization of children would depend on whether new COVID-19 vaccines are adequately 
tested for safety and efficacy in those age groups.
DISCUSSION
This study proposed pandemic frameworks for COVID-19 vaccine allocation by organizing a 
Delphi survey of experts from the fields of vaccination, infectious disease, and public health 
in the Republic of Korea. The results of this survey are in line with those of previous reports 
that focused on initially reducing mortality and protecting the health system.18,19,23,30 
Reduction of transmission was also a fundamental objective, but this approach was difficult 
to apply initially for the following reasons. First, any substantial impact of vaccination 
on reducing transmission would require a mass of individuals to be vaccinated. In the 
early phase, there would not be a sufficient amount of vaccines available for this effective 
transmission-focused strategy. Moreover, ongoing vaccine trials have not been designed to 
estimate the impact on transmission, and evidence of such an impact might not be available 
for some time after approval. Furthermore, considering the lack of data on transmission 
risk groups, it is important to focus on a reasonable group that will clearly benefit from 
vaccination at the start of the vaccination program.
To achieve the goal of reducing mortality and protecting the health system, the WHO and 
COVAX facilities included the following groups as reasonable targets for Tier 1: frontline 
workers in health and social care settings, people over the age of 65 years, and people 
who have underlying comorbidities that put them at higher risk of death.14,30 Similar 
priority groups were proposed in Europe, the UK, Canada, and Australia.31-34 The National 
Academies of Sciences, Engineering, and Medicine (NASEM) and Joint Committee on 
Vaccination and Immunisation (JCVI) also suggested similar concepts but especially 
emphasized high-risk individuals among health and social care workers (in terms of risk of 
transmission to vulnerable persons and acquiring infection) and older adults in congregate 
settings.18,34 Thus, the possible priority groups presented in this study are similar to those 
prioritized by major countries or institutions. Among these priority groups, people with 
comorbid conditions were divided into two groups (significant and moderate) in this study, 
as they accounted for a quarter of the total population. However, the evidence used to classify 
them is still insufficient. In the framework suggested by the NASEM, those with two or more 
high-risk comorbidities were classified as having significant risk, while those with only one 
were classified as having moderate risk.18 In the present study, significant- and moderate-
risk comorbidities were temporarily classified according to the level of evidence presented 
by the Centers for Disease Control.35 This classification may change continuously as data are 
collected, and the classification itself may be meaningless if sufficient amounts of vaccine 
doses are secured at once.
In this study, the ranking of pregnant women was not discussed. Because pregnancy is one of 
the possible conditions that puts women at high risk,35 the ranking needs to be reviewed as 
soon as the vaccine efficacy and safety data are collected. In addition, the ranking of children 
and adolescents was low because of the low mortality rate in this group.36 Although data are 
still limited, this group could be meaningful as a transmission source, as with influenza, and 
the vaccination of this group could be significant in terms of resumption of education and 
reducing outbreaks in the population.37 The ranking of this group will be reviewed as soon as 
more information is collected.
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The framework presented in this study was based on the evidence and epidemiological 
situation as of October 31, 2020. There was a lack of certainty about the characteristics of 
COVID-19 vaccines that could become available in the Republic of Korea, and gaps remain in 
the scientific knowledge of the virus and disease. Because a range of uncertain factors may 
affect the implementation of the framework, these results should be interpreted cautiously, 
and it is necessary to consider various scenarios in advance. First, the vaccination strategy 
against COVID-19 will ultimately be guided by the available vaccines and the outcomes 
against which each vaccine will provide protection. If the efficacy is inferior in older adults or 
people with comorbidities, changes in the framework of the priority target group should be 
considered. It would be helpful to perform mathematical modeling of whether individuals in 
the priority groups in the framework should still be offered vaccination if the vaccine is less 
efficacious for these groups. The actual efficacy is also affected by how well people adhere to 
the basic non-pharmaceutical interventions; therefore, appropriate public health messages 
and education emphasizing such interventions are necessary. Another important issue is 
vaccine safety. Knowledge about vaccine safety from clinical trials is limited. Monitoring 
the side effects and adjusting the allocation framework are necessary steps to minimize 
safety concerns. Transparent communication with the public about the risks and benefits 
of vaccines is crucial. Before moving on to the next step in ranking, it would be necessary to 
make the best effort to vaccinate all prioritized populations. There may also be a scenario 
in which several vaccines with different characteristics are concomitantly approved. For the 
best results, available information should be gathered to determine the optimal vaccine for 
each target group. When multiple vaccines are used, the importance of monitoring efficacy 
and safety must be re-emphasized. The severity of the outbreak will also influence vaccine 
allocation. If the pandemic is severe and a substantial number of people are infected, the 
maintenance of social infrastructure may become a more important objective, and, in this 
case, critical infrastructure workers outside the health sector as well as all healthcare workers 
might take priority. In addition, the route and frequency of administration; stability in 
storage and transportation for each vaccine; and social, economic, and legal aspects may also 
affect the implementation of the framework.
During the study period, data on the characteristics of each vaccine were scarce. Since 
November 2020, phase 3 results of representative vaccine candidates were released,38-40 
and some vaccines were approved and widely administered. The recently published results 
of Phase 3 clinical trials, which focused on the prevention of symptomatic COVID-19 
infection, showed substantially higher efficacy than the minimal recommendation of the 
WHO,17 with some vaccines reportedly having more than 90% efficacy. However, vaccine 
efficacy is considerably decreased depending on the variant strains, highlighting the need 
for monitoring of circulating strains at the time of administration. Some vaccines showed 
similar efficacy in older adults,38,39 while others have not yet been analyzed among older 
adults.41,42 Persons with comorbidities were usually included, but immunocompromised or 
pregnant women were not included in most studies, and there were scarce data on children. 
Vaccination plans and strategies need to be adapted as more information becomes available. 
For this, high-quality surveillance and adequate modeling capacities should be emphasized.
This study presented a framework for allocation and distribution decisions related to 
scarce SARS-CoV-2 vaccines. While reaching consensus, the members of the expert panel 
used information available as of October 31, 2020, to identify priority groups. Flexibility 
in adapting strategies is essential, especially as new information is emerging almost every 
day, which could influence our assessment of priority groups. Although the final decision 
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on vaccine allocation must also take into account national policies on the type and amount 
of vaccine supply, public acceptability, epidemiologic consideration, equity, and other 
factors, this survey provides much needed insight into the decision-making process for 
vaccine allocation at the national level. Furthermore, the process presented here may assist 
policymakers in other countries by providing guidance on how to allocate the COVID-19 
vaccine, at least in the initial stages of deployment.
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